Part of the anti-tumor effect of both FAKi- or FAKi + ERK5i-treated group was due to decreased proliferation as shown by the reduction in Ki-67-positive cancer cells compared to vehicle-treated group (Fig. 6E). This evidence concerns the gene MKI67 and neoplasm.